CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 110 enrolled
Drug / intervention
Saypha Volume Lidocainecombination
Likely dose
Saypha Volume Lidocaine 4 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04883632
NCT04883632N/ACompleted

A Prospective, Randomized, Multicenter Study Evaluating Saypha® VOLUME Lidocaine* for the Correction of Nasolabial Fold

Croma-Pharma GmbH·interventional·Posted May 12, 2021·Updated Apr 3, 2025

In Brief

A clinical study evaluating Saypha Volume Lidocaine for Moderate to Severe Nasolabial Folds. Completed, enrolled 110 participants across 3 sites.

Detailed Summary

Comparison of saypha Volume Lidocaine from 2 different manufacturing locations in correcting moderate to sever nasolabial folds

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 12, 2021
Enrollment StartNov 5, 2019
Primary CompletionMay 27, 2021
Study CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.1 years ago

Interventions

Saypha Volume Lidocainecombination

correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma. The amount injected depended on the size of the area to be corrected and the desired level of soft tissue augmentation. It was estimated that a maximum volume of 4 mL per treatment was needed but should not have exceeded 10 mL in total per treatment or 20 mL per year. and use in respective indications. The investigational device was administered to eligible subjects on investigation Day 0. A touchup treatment at Week 2 was optional at the investigator's discretion if full correction was